EBASTINE. A REASONABLE CHOICE

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract


Data on pharmacokinetics and pharmacodynamics, efficacy and safety of ebastin, a review of clinical studies of therapy of allergic rhinitis, chronic idiopathic urticaria and other dermatoses are presented.

Restricted Access

I S Gushchin

NRC Institute of Immunology FMBA of Russia

Email: igushchin@yandex.ru
24, Kashirskoe Shosse, Moscow, 115478, Russia

I V Danilicheva

NRC Institute of Immunology FMBA of Russia

24, Kashirskoe Shosse, Moscow, 115478, Russia

  1. Rico S, Antonijoan RM, Barbanoj MJ. Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines Journal of Asthma and Allergy. 2009;2:73-92.
  2. Гущин ИС. Аллергическое воспаление и его фармакологический контроль. М.; «Фармарус Принт», 1998. 252 с.
  3. Liu KH, Kim MG, Lee D, Yoon YJ, Kim MJ, Shon JH et al. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metabolism and Disposition. 2006;34:1793-1797.
  4. Гущин ИС. Обратные агонисты Н1-рецепторов как перспективные противоаллергические средства (обзор). Химикофармацевтический журнал. 2010:(1):8388.
  5. Wiseman LR, Faulds D. Ebastine. A review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs. 1996;51:260-277.
  6. Simons FER, Simons KJ. Clinical pharmacolody of new antihistamine H1-receptor antagonists. Clin. Pharmacokinet. 1999;36:329-3521.
  7. Hurst M, Spencer CM. Ebastine: an update ofits use in allergic disorders. Drugs. 2000;59:981-1006.
  8. Pentikis HS, Huyang My Dorr MB, Heald DL. The effect of food on bioavailability of ebastine. Am. J. Ther. 1997;4:80-84.
  9. Pasko P, Rodacki T, Domagala-Rodacka R, Palimonka K, Marcinkowska M, Owczarek D. Second generation H1-antihistamines interaction with food and alcohol-A systematic review. Biomedicine & Pharmacotherapy. 2017;93:27-39.
  10. Yamaguchi T, Hashizume T, Matsuda M, Sakashita M, Fujii T, Sekine Y et al. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittelforschung. 1994;44:59-64.
  11. Frank H Jr, Gillen M, Rohatagi SS, Lim J, George G. Ebastine Study Group. A double-blind placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis. J. Clin. Pharmacol. 2002;42:1097-1104.
  12. Van Cauwenberge P, De Belder T, Sys L. A review of the second-generation antihistamine ebastine for the treatment of allergic disorders. Expert Opin. Pharmacother. 2004;5: 1807-1813.
  13. Lasseter KC, Dilzer SC, Vargas R, Waldman S, Noveck RJ. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study. Clin. Pharmacokinet. 2004;43:121-129.
  14. Noveck RJ, Preston RA, Swan SK. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment. Clin. Pharmacokinet. 2007;46:525-534.
  15. Torrent J, Barbanoj MJ, Lzquierdo L, Segura J, Jané F. Ebastine pharmacokinetics and antihistamine effect in man. Rev Pharmacol Clin Exp. 1988;5:181.
  16. Vincent J, Liminana R, Meredith PA, Reid JL. The pharmacokinetics, antihistamine and concentration effect relationship of ebastine in healthy subjects. Br J Clin Pharmac. 1988;26:497-501.
  17. Frossard N, Benabdesselam O, Purohit A, Mounedji N, Pauli G. Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers. Fundam Clin Pharmacol. 2000;14:409-413.
  18. Antonijoan R, Garcia-Gea C, Puntes M, Perez J, Esbri R, Serra C, Fortea J, Barbanoj MJ. Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults. Clin Ther. 2007;29:814-822.
  19. Campbell A, Michel FB, Bremard-Oury C, Crampette L, Bousquet J. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. Drugs. 1996;52:15-19.
  20. Nori M, Iwata S, Munakata Y et al. Ebastine inhibits T-cell migration, production of Th2-type cytokines and proinflammatory cytokines. Clin Exp Allergy. 2003;33:1544-1554.
  21. Horiguchi T, Tachikawa S, Kasahara J, Shiga M, Kondo R, Miyazaki H. Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma. Clin Drug Invest. 1999;17:435-440.
  22. Ratner P, Hampel F Jr, Gispert J. Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis. Methods Find Exp Clin Pharmacol. 2003;25:111-115.
  23. Ciprandi G, Cirillo I, Mora F, La Rosa M. Ebastine improves nasal symptoms and airflow and affects response to decongestion test in patients with persistent allergic rhinitis: a pilot study. Allergy Asthma Proc. 2007;28:578-581.
  24. Storms WW. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs. 1996;52:20-25.
  25. Ratner PH, Lim JC, Georges GC. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group. J Allergy Clin Immunol. 2000;105:1101-1107.
  26. Bousquet J, Gaudano EM, Palma Carlos AG, Staudinger H. A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Multicentre Study Group. Allergy. 1999;54:562-568.
  27. Picado Valles C, Cadahia Garcia A, Cistero Bahima A, Cano Cantudo L, Sanz Amaro A, Zayas Sanza JM. Ebastine in perennial allergic rhinitis. Ann Allergy. 1991;67:615-618.
  28. De Molina M, Cadahia Garcia A, Cano Cantudo L, Sanz Amaro A. Efficacy and tolerability of ebastine at two dose levels in the treatment of seasonal allergic rhinitis. Drug Invest. 1989;1:40-46.
  29. Pelaez A. Clinical efficacy of ebastine in the treatment and prevention of seasonal allergic rhinitis. Drugs. 1996;52:35-38.
  30. Gehanno P, Bremard-Oury C, Zeisser P Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol. 1996;76:507-512.
  31. Hampel F Jr, Howland W, 3rd, Van Bavel J, Ratner P A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol. 2004;14:56-63.
  32. Davies RJ. Efficacy and tolerability comparison of ebastine 10 and 20 mg with loratadine 10 mg: a double-blind, randomised study in patients with perennial allergic rhinitis. Clin Drug Investig. 1998;16:413-420.
  33. Sastre J. Ebastine in allergic rhinitis and chronic idiopathic urticaria. Allergy. 2008; 89:1-20.
  34. Ciprandi G. Clinical utility and patient adherence with ebastine for allergic rhinitis.Patient Prefer Adherence. 2010;4: 389-395.
  35. Peyri J, Vidal J, Marron J, Fonseca E, Suarez E, Ledo A. Ebastine in chronic urticaria: a double-blind placebo-controlled study. J Dermatolog Treat. 1991;2:51-53.
  36. Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs. 1996;52:30-33.
  37. Magerl M, Schmolke J, Siebenhaar F, Zuberbier T, Metz M, Maurer M. Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy. 2007;62:1465-1468.
  38. Goyal V, Gupta A, Gupta O, Lal D, Gill M. Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria. J Clin Diagn Res. 2017;11:6-9.
  39. Godse KV. Ebastine in chronic spontaneous urticaria in higher doses. Indian J Dermatol. 2011;56:597-598.
  40. Данилычева ИВ, Ильина НИ, Самцов АВ, Разнатовский АВ, Ващенко ЕВ. и соавт. Удвоенная доза Кестина 20 в лечении хронической крапивницы: результаты многоцентрового российского исследования эффективности и безопасности. Вестник дерматологии и венерологии. 2007;(5):6365.
  41. Pecoraro L, Paiola G, Pietrobelli A. Ebastine overdose in a child, Clinical Case Reports, 2017;5:403-405.
  42. Сидоренко ИВ, Захаржевская ТВ, Караулов АВ. Антигистаминные препараты в лечении крапивницы. Лечащий врач. 2004;(5):313.
  43. Елисютина ОГ, Феденко ЕС, Земская ЕН, Штырбул ОВ. Опыт клинического применения эбастина в лечении больных спонтанной крапивницей. Российский Аллергологический Журнал. 2016;(4):81-86.
  44. Roger A, Fortea J, Artés M, Montilla L. Preferred attributes of the new fast dissolving tablet (FDT) formulation of ebastine in patients with allergy. J Outcomes Res. 2006;10:13-22.
  45. Львов А. Кестин в терапии зудящих дерматозов. Врач. 2004;(9):5556.
  46. Перламутров ЮН, Ольховская КБ, Ляпон АО, Айвазова ТВ. Новые возможности в фармакотерапии атопического дерматита. Вестник дерматологии и венерологии. 2017;(3):68-75.
  47. Плиева КТ, Мельниченко ОО, Невозинская ЗА, Корсунская ИМ. Возможности контроля кожных аллергических реакций. Эффективная фармакотерапия. Дерматовенерология и дерматокосметология. 2016;(3): 36.
  48. Цикаришвили НВ, Цискаришвили НИ. Авен50 и эбастин в лечении и профилактике фотодерматозов. Georgian medical news. 2009;(2):5256.
  49. Moss AJ, Chaikin P, Garcia JD, Gillen M, Roberts DJ, Morganroth J. A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy. 1999;29:200-205.
  50. Gillen MS, Miller B, Chaikin P, Morganroth J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol. 2001;52:201-204.
  51. Chaikin P, Gillen MS, Malik M, Pentikis H, Rhodes GR, Roberts DJ. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. Br J Clin Pharmacol. 2005;59:346-354.
  52. Vincent J, Sumner DJ, Reid JL. Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects. Br J Clin Pharmac 1988;26: 503-508.
  53. Brookhuis KA, de Vries G, de Waard D. Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg doses, and triprolidine 10 mg on car driving performance. Br J Clin Pharmac 1993;36:67-70.
  54. Ebastin. Product Monograph. 2001 Almirall Prodesfarma S.A.
  55. Study M/09020/02 Almirall Prodesfarma. Data on file.

Views

Abstract - 4

PDF (Russian) - 0

Refbacks

  • There are currently no refbacks.

Copyright (c) 2017 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies